Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02906397 · ClinicalTrials.gov registry record · Phase 1
Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02906397 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 15 participants.
The verdict
NCT02906397, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
To determine the safety and tolerability of galunisertib when combined with Stereotactic Body Radiotherapy (SBRT) (hypofractionated radiation).
Interventions
- RADIATION Stereotactic Body Radiotherapy (SBRT)
- DRUG Galunisertib 150mg by mouth twice a day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-03-30 |
| Est. Completion | 2021-07-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02906397
The ClinicalTrials.gov registry entry for NCT02906397 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Stereotactic Body Radiotherapy (SBRT) is the first listed.
NCT02906397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02906397 about?
NCT02906397 is a clinical study titled "Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)". To determine the safety and tolerability of galunisertib when combined with Stereotactic Body Radiotherapy (SBRT) (hypofractionated radiation).
What is the current status of trial NCT02906397?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-03-30. Estimated completion is 2021-07-21.
What interventions are being tested in trial NCT02906397?
The interventions under investigation include: Stereotactic Body Radiotherapy (SBRT) (RADIATION), Galunisertib 150mg by mouth twice a day (DRUG).
Who is sponsoring clinical trial NCT02906397?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.